Comparison 6. Combination terbinafine plus azole versus terbinafine monotherapy.

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Clinical cure	1		Risk Ratio (M‐H, Random, 95% CI)	Totals not selected
1.1 Short‐term follow‐up (≤ 52 weeks)	1		Risk Ratio (M‐H, Random, 95% CI)	0.0 [0.0, 0.0]
1.2 Long‐term follow‐up (> 52 weeks)	0		Risk Ratio (M‐H, Random, 95% CI)	0.0 [0.0, 0.0]
2 Mycological cure	1		Risk Ratio (M‐H, Random, 95% CI)	Totals not selected
2.1 Short‐term follow‐up (≤ 52 weeks)	0		Risk Ratio (M‐H, Random, 95% CI)	0.0 [0.0, 0.0]
2.2 Long‐term follow‐up (> 52 weeks)	1		Risk Ratio (M‐H, Random, 95% CI)	0.0 [0.0, 0.0]
3 Adverse events	1		Risk Ratio (M‐H, Random, 95% CI)	Totals not selected